Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/YTHDC1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/YTHDC1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/YTHDC1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/YTHDC1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/YTHDC1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/YTHDC1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/YTHDC1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005102813 | Prostate | Tumor | mRNA transport | 38/3246 | 130/18723 | 5.44e-04 | 3.96e-03 | 38 |
GO:000024512 | Prostate | Tumor | spliceosomal complex assembly | 26/3246 | 79/18723 | 5.68e-04 | 4.11e-03 | 26 |
GO:003144011 | Prostate | Tumor | regulation of mRNA 3'-end processing | 11/3246 | 28/18723 | 4.97e-03 | 2.43e-02 | 11 |
GO:00400291 | Prostate | Tumor | regulation of gene expression, epigenetic | 29/3246 | 105/18723 | 5.72e-03 | 2.66e-02 | 29 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:190331125 | Skin | AK | regulation of mRNA metabolic process | 81/1910 | 288/18723 | 7.27e-18 | 8.61e-15 | 81 |
GO:004348428 | Skin | AK | regulation of RNA splicing | 54/1910 | 148/18723 | 9.66e-18 | 9.53e-15 | 54 |
GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
GO:000037526 | Skin | AK | RNA splicing, via transesterification reactions | 85/1910 | 324/18723 | 1.16e-16 | 7.62e-14 | 85 |
GO:000037726 | Skin | AK | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:000039826 | Skin | AK | mRNA splicing, via spliceosome | 84/1910 | 320/18723 | 1.69e-16 | 9.11e-14 | 84 |
GO:005068420 | Skin | AK | regulation of mRNA processing | 47/1910 | 137/18723 | 1.92e-14 | 7.57e-12 | 47 |
GO:004802427 | Skin | AK | regulation of mRNA splicing, via spliceosome | 39/1910 | 101/18723 | 3.87e-14 | 1.43e-11 | 39 |
GO:007182628 | Skin | AK | ribonucleoprotein complex subunit organization | 61/1910 | 227/18723 | 7.85e-13 | 2.02e-10 | 61 |
GO:002261828 | Skin | AK | ribonucleoprotein complex assembly | 58/1910 | 220/18723 | 6.75e-12 | 1.33e-09 | 58 |
GO:000038020 | Skin | AK | alternative mRNA splicing, via spliceosome | 30/1910 | 77/18723 | 2.57e-11 | 4.90e-09 | 30 |
GO:000691320 | Skin | AK | nucleocytoplasmic transport | 69/1910 | 301/18723 | 7.63e-11 | 1.29e-08 | 69 |
GO:005116920 | Skin | AK | nuclear transport | 69/1910 | 301/18723 | 7.63e-11 | 1.29e-08 | 69 |
GO:000170120 | Skin | AK | in utero embryonic development | 75/1910 | 367/18723 | 3.09e-09 | 2.62e-07 | 75 |
GO:000038120 | Skin | AK | regulation of alternative mRNA splicing, via spliceosome | 23/1910 | 60/18723 | 7.70e-09 | 5.12e-07 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YTHDC1 | SNV | Missense_Mutation | novel | c.1038N>A | p.Ser346Arg | p.S346R | | protein_coding | tolerated(0.3) | benign(0.157) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YTHDC1 | SNV | Missense_Mutation | | c.485N>A | p.Arg162His | p.R162H | | protein_coding | tolerated_low_confidence(0.08) | benign(0.361) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YTHDC1 | SNV | Missense_Mutation | | c.937N>T | p.Asp313Tyr | p.D313Y | | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AQ-A1H2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | SD |
YTHDC1 | SNV | Missense_Mutation | rs766073192 | c.561N>G | p.Ser187Arg | p.S187R | | protein_coding | deleterious_low_confidence(0) | benign(0.191) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
YTHDC1 | SNV | Missense_Mutation | | c.92A>G | p.Tyr31Cys | p.Y31C | | protein_coding | tolerated_low_confidence(0.26) | probably_damaging(0.996) | TCGA-AR-A2LQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
YTHDC1 | SNV | Missense_Mutation | | c.1165N>A | p.Leu389Ile | p.L389I | | protein_coding | deleterious(0.05) | benign(0.174) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
YTHDC1 | SNV | Missense_Mutation | rs756562328 | c.2044N>T | p.Arg682Trp | p.R682W | | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.649) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
YTHDC1 | SNV | Missense_Mutation | novel | c.713A>T | p.Glu238Val | p.E238V | | protein_coding | tolerated_low_confidence(0.08) | benign(0.006) | TCGA-E9-A243-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
YTHDC1 | insertion | Nonsense_Mutation | novel | c.260_261insCCAATTCTCTGATGTTTAAAGA | p.Lys88GlnfsTer6 | p.K88Qfs*6 | | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YTHDC1 | SNV | Missense_Mutation | novel | c.280G>A | p.Glu94Lys | p.E94K | | protein_coding | deleterious_low_confidence(0.01) | benign(0.051) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |